GlassScriptPhysician profile
William H Dunn
NPI 1669447504
$4,014.73
in general payments reported to CMS, 2019-2025
31 companies · $1,102 in 2025
The $1,102 reported for 2025 was more than what 84% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $93.10 · 2021: $199 · 2022: $264 · 2023: $1,016 · 2024: $1,190 · 2025: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,307.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $903.66 | 2020-2025 | Prolaris |
| Bayer Healthcare Pharmaceuticals INC. | $518.92 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $416.96 | 2023-2025 | Orgovyx, Gemtesa |
| Janssen Biotech, INC. | $345.61 | 2022-2025 | Erleada, Akeega, Balversa |
| Merck Sharp & Dohme LLC | $240.75 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Urogen Pharma, INC. | $237.93 | 2023-2025 | Jelmyto |
| Endo USA, INC. | $161.17 | 2024-2025 | Xiaflex, Aveed, Edex |
| Dendreon Pharmaceuticals LLC | $122.66 | 2024-2025 | Provenge |
| Blue Earth Diagnostics | $112.91 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $111.12 | 2024-2025 | |
| Tolmar, INC. | $104.62 | 2023-2025 | Eligard, Jatenzo |
| Pfizer INC. | $98.14 | 2023-2025 | |
| Procept Biorobotics Corporation | $89.78 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
| Progenics Pharmaceuticals, INC. | $80.85 | 2022-2024 | Pylarify |
| Roche Diagnostics Corporation | $72.49 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accord Healthcare, INC. | $65.44 | 2024-2025 | |
| Teleflex LLC | $60.54 | 2023-2024 | Urolift |
| Acerus Pharmaceuticals Corporation | $33.40 | 2021-2022 | |
| Profound Medical Corp. | $25.17 | 2025 | Tulsa-Pro |
| Ferring Pharmaceuticals INC. | $23.08 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $22.74 | 2020 | |
| Palette Life Sciences, INC. | $21.24 | 2022 | |
| Abbvie INC. | $20.15 | 2024 | |
| Amgen INC. | $19.62 | 2023 | Xgeva |
| Clarus Therapeutics INC. | $17.34 | 2021 | |
| Astellas Pharma US INC | $16.67 | 2020 | |
| Boston Scientific Corporation | $15.75 | 2021 | |
| Smith+Nephew, INC. | $15.16 | 2023 | Stravix Pl |
| Endo Pharmaceuticals INC. | $13.99 | 2024 | Aveed, Edex, Xiaflex |
| Tempus Ai, INC | $13.71 | 2024 | |
| Sun Pharmaceutical Industries INC. | $13.16 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.